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Abstract 
Background: The Kampo medicine bofutsushosan (BTS; Pulvis ledebouriellae compositae; Fang Feng Tong Sheng San) 
has been used as an anti-obesity treatment in overweight patients. In this study, we assessed the underlying physi-
ological changes induced by BTS in obese mice maintained on a high-fat diet.
Methods: Male ICR mice were fed a 60% kcal fat diet for 5 weeks starting at 4 weeks of age and then fed the same 
diet with administration of water (control) or aqueous BTS extract (1.0–2.0 g/kg) for 25 days. Body weight, wet weight 
of isolated white adipose tissue, and obesity-related serum parameters (glucose, lipids, leptin, adiponectin) were 
measured after treatment. The mRNA expression levels of leptin, adiponectin, and UCP1 in the adipose tissues were 
determined by quantitative real-time polymerase chain reaction after the first 5 days of treatment.
Results: Bofutsushosan (1.5–2.0 g/kg) significantly decreased total body weight and total wet weight of white adi-
pose tissue isolated from subcutaneous (retroperitoneal) and visceral regions (epididymal, mesenteric, and perirenal). 
At 2.0 g/kg, BTS also decreased total fat mass, visceral fat mass, and ratio of fat mass to body weight as measured 
by computed tomography, and significantly decreased epididymal adipocyte size after 14 and 25 days’ treatment. 
Twenty-five days’ treatment lowered serum glucose, insulin, leptin, and triglycerides, and reduced homeostasis model 
assessment-insulin resistance. Alternatively, 2.0 g/kg BTS significantly increased mRNA levels of adiponectin, leptin, 
and UCP1 in interscapular brown adipose tissue but not epididymal white adipose tissue after 5 days’ administration.
Conclusion: In the early administration period, BTS increased mRNA expression levels of leptin, adiponectin, and 
UCP1 in brown adipose tissues. With longer administration, BTS improved insulin resistance, and subsequently 
reduced serum levels of leptin and triglyceride in parallel with decreased visceral white adipose tissue volume and 
adipocyte size.
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Background
Obesity rates are increasing worldwide [1], resulting in 
progressively greater incidences of associated health 
problems such as type 2 diabetes mellitus, ischemic 
heart disease, stroke, and cancer. Obesity results from an 
imbalance between food intake and energy consumption 
(basal metabolism and volitional energy expenditure). 
Excessive caloric intake due to the ample availability of 
energy-dense meals is thought to be the main contributor 
to global obesity [2].
Foods that are rich in fats also increase body weight 
induce diabetes in mice and rats [3]. Indeed, many stud-
ies have characterized the pathological responses of ani-
mals to high-fat diets [4, 5]. Although the pathogenesis 
of obesity is complex; the key factor is long-term deregu-
lation of energy balance due to increased energy intake 
and/or reduced energy expenditure. Mammals have 
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evolved chemical energy-storing white adipose tissue and 
energy-dissipating brown adipose tissue [6, 7] to regulate 
energy balance. White adipose tissue enables humans to 
survive for longer periods between meals, storing energy 
mainly as triglycerides, and releasing fatty acids during 
fasting. White adipocytes contain a large single, spherical 
lipid vacuole, and a peripherally located nucleus but few 
mitochondria. Fat storage is regulated by complex endo-
crine signaling between white adipose tissue and the cen-
tral nervous system (CNS), mediated by hormones such 
as leptin and adiponectin. Several groups have demon-
strated that administration of adiponectin increases fatty 
acid oxidation in muscle and decreases hepatic glucose 
production, resulting in amelioration of insulin resist-
ance and improved glucose metabolism in diabetic mice. 
Conversely, decreased adiponectin and increased leptin 
in serum contribute to the development of metabolic 
complications in obesity, particularly diabetes and insulin 
resistance [8–13].
In addition to lifestyle interventions, obese individu-
als can be treated by pharmacological therapy. The com-
plex Kampo herbal formulation bofutsushosan (BTS; 
Pulvis ledebouriellae compositae; Fang Feng Tong Sheng 
San), consisting of 18 crude components, has been used 
as an anti-obesity drug in overweight patients, where it 
reduces hypertension, insulin resistance, and subcutane-
ous abdominal fat thickness. In addition, BTS has been 
reported to exert anti-obesity effects in various obese and 
diabetic mouse models [14–16]. We have investigated the 
anti-diabetic actions of BTS in the streptozotocin (STZ) 
diabetic mouse and found efficacy similar to that of the 
anti-diabetic drug [17, 18]. One BTS component, Gar-
denia, improved insulin resistance and repaired insulin 
signaling via upregulation of P-Akt, glucose transporter 
4, and glucose uptake in skeletal muscle of STZ-diabetic 
mice [19]. However, anti-obesity actions of BTS were not 
investigated in STZ-diabetic mice.
Uncoupling protein (UCP) 1 is specifically expressed in 
the mitochondrial inner membrane of brown adipocytes, 
where it generates heat by uncoupling oxidative phospho-
rylation. The induction of thermogenesis is controlled by 
the cold–warm centers in the CNS through β3 adrener-
gic signaling. The expression of UCP1 therefore regulates 
thermogenesis, energy expenditure, and oxidative stress, 
processes associated with the pathogenesis of obesity [20, 
21]. Upregulation of UCP1 by genetic manipulations or 
pharmacological agents can reduce obesity and improve 
insulin sensitivity [22, 23]. In the present study, we inves-
tigated the effects of BTS on the mRNA expression lev-
els of UCP1, adiponectin, and leptin in adipose tissue, as 
well as insulin resistance, serum triglycerides, white adi-
pocyte size, and white adipose tissue weight in high-fat 
diet-fed obese model mice.
Methods
Animals
Male ICR mice (8 weeks of age) fed a 60% kcal fat diet 
(D12492, Research Diets Inc, New Brunswick, USA) for 
4 weeks from 4 weeks of age were purchased from Japan 
SLC (Shizuoka, Japan). Mice were acclimated for 1 week 
in a conventional mouse breeding room at Hokuriku 
University with water ad  libitum and kept at 25–26  °C 
with lights on from 7 a.m. to 7 p.m. Mice were then ran-
domly divided into four groups, one control group and 
three BTS dosage groups, with eight mice per group. The 
animal studies were performed following the ARRIVE 
guideline (Additional file 1). The Ethics Review Commit-
tee for Animal Experimentation of Hokuriku University, 
Kanazawa, Japan approved the experimental protocol 
(Additional file 1). The studies were also provided infor-
mation described in Minimum Standards of Reporting 
Checklist(Additional file  2) and summary of all data-
sets in Figs. 1, 2, 3, 4, 5, 6 and 7, and Table 2 (Additional 
file 3).
Preparation and administration of drugs
Bofutsushosan was prepared from 18 crude com-
ponents: Glycyrrhiza, Rhubarb, Gardenia, Ephedra, 
Mirabilite, Forsythia, Ginger, Scutellaria, Schizone-
peta, Platycoden, Mentha, Peony, Atractylodes, Cnid-
ium, Glypsum, Saposhnikovia, Angelica, and Talcum 
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Fig. 1 Effects of BTS on body weight in high-fat diet-fed obese mice. 
ICR mice (4 weeks of age) were provided a high-fat diet for 5 weeks 
ad libitum. Doses (0, 1.0, 1.5, and 2.0 g/kg) of BTS were administered 
orally to obese mice at 9 weeks of age for 25 days under continued 
high-fat diet. Body weights were measured on days 0, 6, 12, 18, and 
25 during administration. Body weight changes were calculated from 
day 0 before administration of BTS to day 25. Values are expressed as 
mean ± SD (n = 6–8). Differences between group means were evalu-
ated by Tukey’s or Scheffe’s tests. *P < 0.05, **P < 0.01: significantly 
different from control water group without BTS
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gift from Kobayashi Pharmaceutical Co Ltd. (Ibaraki, 
Osaka, Japan). A mixture of cut crude components 
(Table 1) was extracted in 10 volumes of distilled water 
for 30  min at >90  °C. The extracted solution was fil-
tered, concentrated by vacuum, and spray-dried. The 
yield of dried BTS extract was 18.5% (w/w) and con-
tained 0.80% geniposide, 2.77% baicalin, 0.1% senno-
side A, 0.14% total alkaloids, 0.71% glycyrrhizic acid, 
and 0.26% paeoniflorin. For experiments, BTS doses 
of 1.0, 1.5, and 2.0  g/kg body weight were selected 
Fig. 2 Effects of BTS on total white adipose tissue wet weight (a) and individual wet weights of retroperitoneal, epididymal, mesenteric, and perire-
nal white adipose tissues (b) in obese mice orally administered various doses (0, 1.0, 1.5, and 2.0 g/kg) of BTS for 25 days under a high-fat diet. White 
adipose tissues were isolated from obese mice and wet weights measured. Values are expressed as mean ± SD (n = 5–7). Differences between 
group means were evaluated by Tukey’s or Scheffe’s tests. *P < 0.05, **P < 0.01: significantly different from control water group without BTS
Control
(Without BTS)
                 With BTS                (P Value)
Total Fat 
Mass (cm2)
10.24 ± 4.07                 2.09 ± 1.21             (P=0.029)
Visceral Fat 
Mass (cm2)
  6.82 ± 2.69                 1.38 ± 1.02            (P=0.031)




Fat Muscles and Organs
Fig. 3 Effects of BTS (2.0 g/kg) on total fat mass, visceral fat mass, and body fat percentage in obese mice measured by computed tomography. 
Shown is a typical example of fat mass. Purple areas are fat masses, and blue areas are skeletal muscle and organ masses. Body fat percentage was 
calculated as [area of fat mass]/[(area of fat mass) + (area of muscle and organ masses)] × 100. Values expressed as mean ± SD (n = 3). P values in 
parenthesis were calculated by Student’s t test. P < 0.05, BTS group is significantly different from control group without BTS
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because lower doses (0.25 and 0.5  g/kg) did not affect 
the body weight of obese model mice. Solutions con-
taining 20, 30, and 40 mg/mL were prepared for the 1.0, 
1.5, and 2.0 g/kg dose groups, respectively, as the obese 
mice (ca. 60 g) drank approximately 3 mL of water/day 
with or without BTS. These solutions of BTS extracts 
were totally soluble in the water. The stability of BTS 
extracts in the water is not confirmed but the extracted 
solutions were prepared every day for 25 days in such a 
way as to any other traditional Chinese medicine did. 
Solutions were administered orally to the 9-week old 
obese mice for 25  days under free intake of the high-
fat diet while control group mice received equivolume 
water under the same high-fat diet. The volume of BTS 
solution consumed was checked daily and an insuffi-
cient volume was directly administered by syringe up 
to 3  mL/day. Body weights of BTS-treated and con-
trol mice were measured on day 0, 6, 12, 18, and 25 of 
administration.
Measurement of serum glucose, insulin, leptin, 
adiponectin, triglyceride, and cholesterol
Blood was collected from the neck vein plexus of anesthe-
tized mice after administration of BTS solution or water 
for 25 days. Blood samples were centrifuged at 2000g for 
5 min at 25 °C and the supernatant was used as the serum 
sample. Serum glucose concentration was measured 
by the glucose oxidase method using a serum glucose 
monitor (Medisafe Mini, Termo, Tokyo, Japan). Serum 
insulin was measured using a mouse enzyme linked 
immunosorbent assay (ELISA) kit for insulin (Morinaga, 
Yokohama, Japan). The homeostasis model assessment-
insulin resistance (HOMA-IR) value was calculated as 
[serum glucose (mg/dL) ×  serum insulin (μU/mL)]/405 
[24]. Serum leptin and adiponectin were measured with 
mouse Leptin and Adiponectin/Acrp30 Quantikine 
ELISA kits (R&B Systems, Minneapolis, USA). Serum 
triglyceride was measured using the Wako Triglyceride 
E Test (Wako, Osaka). High-density lipoprotein (HDL) 
Fig. 4 Effects of BTS (2.0 g/kg) on visceral epididymal adipocyte size under optical microscopy (a) and scanning electron microscope at ×300 mag-
nification (b) after 14 days’ administration and epididymal adipocyte size under optical microscopy after 14 and 25 days (c). Values are expressed as 
mean ± SD (n = 1 and 3, respectively). Difference between group means was evaluated by Student’s t test. *P < 0.05: significantly different from 
control water group without BTS
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cholesterol and low-density lipoprotein (LDL) cholesterol 
were measured using HDL and LDL/VLDL-cholesterol 
Quantification Kits (Bio Vision, Milpitas, USA).
Isolation of white and brown adipose tissue
After treatment, mice were euthanized by cervical dislo-
cation, and white adipose tissues isolated from the ret-
roperitoneal subcutaneous region and the epididymal, 
mesenteric, and perirenal viscera. Wet weights of these 
isolated adipose tissue samples were measured. In some 
experiments, epididymal white adipose tissue and inter-
scapular brown adipose tissue were isolated from eutha-
nized obese mice administered BTS (2.0  g/kg) or water 
for 5 days and stored in ISOGEN reagent (Nippon Gene, 
Tokyo) for gene expression analysis (below).
Measurement of total, subcutaneous, and visceral fat 
masses and percent body fat
Total fat, subcutaneous fat, visceral fat, and muscle/
organ masses were measured using a computed tomog-


























































Fig. 5 Effects of BTS on serum glucose (a), serum insulin (b) and HOMA-IR value (c) in obese mice. HOMA-IR value was calculated as [serum glucose 
(mg/dL) × serum insulin (μU/mL)]/405. Doses of BTS (0, 1.0, 1.5, and 2.0 g/kg) were administered orally to obese mice (9 weeks of age) for 25 days 
under a high-fat diet. Values are expressed as mean ± SD (n = 6). Differences between group means were evaluated by Tukey’s or Scheffe’s tests. 
*P < 0.05, **P < 0.01: significantly different from control water group without BTS
Fig. 6 Effects of BTS on serum leptin (a) and serum adiponectin (b) 
in obese mice. Doses of BTS (0, 1.0, 1.5, and 2.0 g/kg) were admin-
istered orally to obese mice (9 weeks of age) for 25 days under a 
high-fat diet. Values expressed as mean ± SD (n = 6–7). Differences 
between group means were evaluated by Tukey’s or Scheffe’s tests. 
**P < 0.01: significantly different from control water group












































































Fig. 7 Effects of BTS on serum triglyceride (a), serum HDL-cholesterol (b), and serum LDL-cholesterol (c) in obese mice. Doses of BTS (0, 1.0, 1.5, and 
2.0 g/kg) were administered orally to obese mice (9 weeks of age) for 25 days under a high-fat diet. Values are expressed as mean ± SD (n = 6–7). 
Differences between group means were evaluated by Tukey’s test. *P < 0.05, **P < 0.01: significantly different from control water group without BTS
Table 1 Components of bofutsushosan (BTS)
a Each value (%) is the component rate of BTS
Components Component rate (%)
Glycyrrhizae Radix (Glycyrrhiza) 7.39a
Rhei Rhizoma (Rhubarb) 5.55
Gardeniae Fructus (Gardenia) 4.41
Ephedrae Herba (Ephedra) 4.41
Natrium Sulfuricum (Mirabilite) 5.55
Forsythiae Fructus (Forsythia) 4.41
Zingiberis Rhizoma (Ginger) 1.13
Scutellariae Radix (Scutellaria) 7.39
Schizonepetae Spica (Schizonepeta) 4.41
Platycodi Radix (Platycoden) 7.39
Menthae Folium (Mentha) 4.41
Paeonia Radix (Peony) 4.41
Atractyloids Lanceae Rhizoma (Atractylodes) 7.39
Cnidii Rhizoma (Cnidium) 4.41
Gypsum Fibrosum (Gypsum) 7.39
Saposhnikoviae Radix (Saposhnikovia) 4.41
Angelicae Radix (Angelica) 4.41
Talcum Crystallinum (Talcum) 11.1
Table 2 Effects of  BTS on  mRNA expression of  leptin, adi-
ponectin, UCP1, and UCP2 in interscapular brown adipose 
tissue and  epididymal white adipose tissues after  5  days’ 
administration
Relative quantification of mRNA expression by real-time PCR was calculated 
relative to β-actin mRNA. Values are expressed as mean ± SD (n = 4–9). P values 
were calculated by Student’s t test. P < 0.05, BTS group is considered significantly 
different from control group without BTS
−BTS +BTS P value
Interscapular brown adipose tissue
 Leptin 0.0264 ± 0.0080 0.1182 ± 0.0612 0.0004
 Adiponectin 0.7679 ± 0.2436 2.5412 ± 2.1369 0.0250
 UCP1 2.2519 ± 0.9376 3.3746 ± 0.6704 0.0100
 UCP2 0.0717 ± 0.0210 0.0833 ± 0.0430 0.4781
Epididymal white adipose tissue
 Leptin 0.0512 ± 0.0243 0.0390 ± 0.0203 0.3756
 Adiponectin 0.6115 ± 0.5319 0.9395 ± 0.4682 0.1839
 UCP1 0.0015 ± 0.0008 0.0020 ± 0.0014 0.5207
 UCP2 0.1560 ± 0.0252 0.1777 ± 0.0930 0.5347
following 25 days’ treatment. Percent body fat was calcu-
lated using the following formula: [area of fat mass]/[(area 
of fat mass) + (area of muscle and organ masses)] × 100.
Measurement of adipocyte size in epididymal adipose 
tissue
Small pieces of epididymal adipose tissue were iso-
lated from euthanized obese mice after 14 and 25 days’ 
treatment with BTS or water, fixed with 10% formalin, 
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embedded in paraffin, sectioned, and stained with hema-
toxylin and eosin. To estimate the size of adipocytes, 
cross-sectional areas of six randomly selected adipo-
cytes per section were measured at magnification using 
ImageJ software (National Institutes of Health, Bethesda, 
USA).
Scanning electron microscopy
Epididymal adipose tissues from euthanized obese mice 
treated with BTS or water for 14 days were fixed with 2% 
glutaraldehyde in HEPES buffer, post-fixed in 2% osmium 
tetroxide, incubated in 50, 70, 90, 95, and 100% etha-
nol, and dehydrated in butanol. After lyophilization and 
sectioning, tissues were examined by scanning electron 
microscopy at 300× magnification.
Quantitative real‑time PCR for mRNA analysis
The mRNA expression levels of UCP1, UCP2, leptin, 
adiponectin, and β-actin (as an internal control) in inter-
scapular brown and epididymal white adipose tissues 
were determined by quantitative real-time polymerase 
chain reaction (qRT-PCR). Total RNA was extracted 
using ISOGEN reagent according to the manufac-
ture’s instruction (Wako). First-strand cDNAs were 
synthesized using Moloney Murine Leukemia Virus 
(M-MLV) reverse transcriptase (Invitrogen, Carlsbad, 
CA). Reverse transcription (RT) reactions were carried 
out in 75  mM KCl, 50  mM Tris–HCl (pH 8.3), 3  mM 
MgCl2, 10  mM dithiothreitol (DTT), 0.5  mM each of 
dATP, dCTP, dGTP, and dTTP, 40 units of recombinant 
ribonuclease inhibitor (RNaseOUT™, Invitrogen), 0.5 μg 
of Oligo(dT)12–18 primer (Invitrogen), total RNA, and 
200 units of the M-MLV reverse transcriptase in a final 
volume of 20  μL at 37  °C for 50  min. Real-time PCR 
was performed in a final volume of 25  μL containing 
0.5  μM forward and reverse primers, 12.5  μL GeneAce 
SYBR qPCR Mix Low Rox (Nippon Gene) and 1  μL 
of prepared cDNA template using an ABI 7500 Real-
Time PCR System (Applied Biosystems, Foster City, 
CA). The primers were designed using Primer Express 
software (Applied Biosystems) and had the following 
sequences: for UCP1, forward 5′-ACAGAAGGATT-
GCCGAAACTGT-3′ and reverse 5′-GTCGTAGAG-
GCCAATCCTGAGT-3′ (69  bp product); for UCP2, 
forward 5′-CTCCCTTGCCACTTCACTTCTG-3′ and 
reverse 5′-CATGTATCTCGTCTTGACCACATCA -3′ 
(66  bp product); for leptin, forward 5′-TCAAGCAGT-
GCCTATCCAGAAA-3′ and reverse 5′-GGTGAAGCC-
CAGGAATGAAG-3′ (146 bp product); for adiponectin, 
forward 5′-TGTATCGCTCAGCGTTCAGTGT-3′ and 
reverse 5′-TCCCGGAATGTTGCAGTAGAA-3′ 
(140  bp product); for β-actin, forward 5′-AGG-
GAAATCGTGCGTGACAT-3′, and reverse 
5′-GAACCGCTCGTTGCCAATAG-3′ (131 bp product). 
Target gene expression was calculated relative to β-actin 
expression.
Statistical analyses
All values are expressed as mean  ±  SD. Differences 
between group means were evaluated by one-way analy-
sis of variance followed by Tukey’s or Scheffe’s multiple 
range tests using Mac Toukei-Kaiseki Ver.2.0 (Esumi, 
Tokyo). When variance within each group is similar or 
different between groups, Tukey’s test or Scheffe’s test 
was used respectively. In some experiments, differences 
between two groups were analyzed by Student’s t test. A 
value of P  <  0.05 was considered statistically significant 
from the control water group without BTS.
Results
Effects of BTS on body and adipose tissue weights 
in high‑fat diet‑fed obese mice
The high-fat diet (D12492) significantly increased body 
and adipose white tissue weights of ICR mice compared 
to normal diet (D12450) (data not shown). Changed 
body weight in vertical axis of Fig.  1 was shown as dif-
ference from body weight of same mice at day 0 without 
administration of BTS. Body weight change (day 6 to day 
25) was significantly reduced in the obese mouse group 
administered BTS (1.0–2.0 g/kg) (Fig. 1). At day 25, Body 
weight was significantly reduced in the obese mouse group 
administered 2.0 g/kg BTS compared to the water-admin-
istered control group [45.9 ± 3.8 g (n = 7) vs. 59.0 ± 9.5 g 
(n = 6), P < 0.05] but not in groups receiving 1.0 or 1.5 g/
kg BTS [55.9 ± 8.5 g (n = 8) and 48.0 ± 4.6 g (n = 6)]. In 
addition, the wet weights of white adipose tissues isolated 
from the subcutaneous retroperitoneal area and epididy-
mal, and perirenal viscera were significantly lower in the 
1.5 and 2.0  g/kg BTS groups compared to control obese 
mice (Fig. 2). In contrast, BTS without Gardenia (2.0 g/kg) 
did not influence body weight or total white adipose tissue 
wet weight (data not shown). Figure 3 shows typical com-
puted tomography results from mice treated with BTS for 
25 days (purple areas show fat masses and blue areas skel-
etal muscle and organ masses). BTS (2.0 g/kg) significantly 
reduced total fat mass area, visceral fat mass area, and per-
cent body fat compared to water controls. These results 
suggest that BTS decreases the body weight of obese mice, 
at least in part, by reducing white adipose tissue weight.  
Effects of BTS on adipocyte size
Administration of 2.0  g/kg BTS for 14  days appeared to 
reduce epididymal adipocyte size compared to controls as 
revealed by both light microscopy (Fig. 4a) and scanning 
electron microscopy (Fig. 4b). Quantitative analysis indi-
cated that BTS significantly reduced average epididymal 
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adipocyte area after 25  days’ treatment (Fig.  4c). These 
results demonstrate that BTS can inhibit hypertrophy of 
visceral adipocytes (a sign of lipid storage) in obese mice.
Effects of BTS on the mRNA expression levels of leptin, 
adiponectin, UCP1, and UCP2 in brown and white adipose 
tissue
Expression levels of leptin, adiponectin, UCP1, and UCP2 
were compared between interscapular brown adipose tis-
sue and epididymal white adipose tissue in control obese 
mice. Expression levels of leptin, adiponectin, and UCP2 
mRNAs were similar in brown and white adipose tis-
sue. However, expression of UCP1 mRNA was 1500-fold 
greater in brown adipose tissue than white adipose tis-
sue (Table 2). Administration of BTS (2.0 g/kg) to obese 
mice for 5 days significantly increased mRNA expression 
levels of leptin, adiponectin, and UCP1 in brown adipose 
tissue (Table 2) compared to water-treated controls, with 
greater facilitation of leptin and adiponectin compared to 
UCP1. In contrast, BTS did not affect mRNA expression 
levels of these factors in white adipose tissue (Table  2). 
However, there was no changes in the wet weights of 
brown and white adipose tissues in obese mice during the 
5 day administration of BTS (unpublished observations).
Effects of BTS on serum glucose, insulin, leptin, 
and adiponectin
Serum levels of glucose and insulin in ICR mice fed a 
normal-fat diet (D12450) were 73.3  ±  33.1  mg/dL and 
5.59 ± 2.10 ng/mL, respectively, for a HOMA-IR value of 
24.6 ± 11.3. Serum glucose, insulin, and HOMA-IR were 
all significantly elevated in control obese mice, increases 
partially reversed in mice receiving BTS (1.0–2.0 g/kg) for 
25  days (Fig.  5). Similarly, BTS reduced serum leptin in 
obese mice (Fig. 6), but did not alter serum adiponectin.
Effects of BTS on serum triglyceride, HDL‑cholesterol, 
and LDL‑cholesterol
BTS (1.5–2.0 g/kg) significantly lowered serum triglycer-
ide levels in obese mice but had no effect on serum HDL-
cholesterol or LDL-cholesterol (Fig. 7).
Discussion
Expansion of visceral adipose tissue in obese individuals 
contributes to the development of obesity-related disor-
ders such as diabetes mellitus, hyperlipidemia, hyperten-
sion, and metabolic syndrome [1, 2]. It is thus critical to 
suppress visceral adipose tissue growth to prevent these 
disorders. In the present study, we demonstrate time- 
and dose-dependent benefits of BTS on visceral adipose 
tissue weight, obesity-related serum indices, and endo-
crine signals in high-fat diet-fed obese mice. Consump-
tion of BTS (1.0–2.0  g/kg/day) decreased body weight 
(Fig.  1), and this reduction was significant in the 2.0  g/
kg/day BTS dose group after 25 days’ administration even 
without diet modification. Daily doses of 1.5 and 2.0 g/kg 
also significantly reduced accumulation of visceral and 
subcutaneous adipose tissue after 25  days’ treatment as 
determined by direct weighing (Fig. 2) and CT examina-
tion (Fig. 3) compared to control obese mice. Histological 
study demonstrated that BTS significantly reduced the 
average size of epididymal white adipocytes (Fig. 4) com-
pared to controls, suggesting that suppression of visceral 
white adipocyte hypertrophy accounts for the reductions 
in tissue and body weight. In contrast to obese mice, BTS 
(3.0 g/kg/day) had no effect on the body weight and no 
toxic effect in age-matched ICR normal mice, although 
some mice have a tendency of increased loose feces 
(unpublished observation). In addition, BTS without 
Gardenia (2.0  g/kg, negative control) did not influence 
body or adipose tissue weight (unpublished observation). 
Thus, BTS specifically reduced whole-body weight by 
suppressing the increase in white adipose tissue weight 
resulting from a high-fat diet. This result parallels obser-
vations in obese humans, although the chosen doses of 
BTS were greater than the human clinical dose (0.095 g/
kg) [25].
The mRNA expression level of UCP1 in interscapu-
lar brown adipose tissue was approximately 1500-fold 
greater than that in epididymal white adipose tissue 
(Table  2), suggesting that the physiological functions of 
UCP1, such as thermogenesis, predominate in brown 
adipose tissue of obese mice. UCP1 gene expression has 
been reported to increase in response to changes in tem-
perature and dietary fat as well as in response to non-
esterified fatty acids, adrenergic β3-agonists, and high 
intracellular cyclic AMP [26]. Upregulation of UCP1 
by genetic manipulations or pharmacological agents 
can reduce obesity and improve insulin sensitivity [22, 
23]. Administration of BTS for only 5  days upregulated 
UCP1 mRNA expression  1.5-fold compared to control 
obese mice, but did not affect the expression level of 
UCP2 mRNA in either brown or white adipose tissue 
(Table  2). These results suggest that BTS may increase 
energy expenditure by promoting UCP1-mediated pro-
cesses in brown adipose tissues during the early stage 
of BTS administration. Despite this increase in UCP-1 
mRNA expression, there was no changes in the wet 
weights of brown and white adipose tissues in obese 
mice during this early period (unpublished observations). 
These results suggest that BTS may decrease the size and 
weight of visceral adipose tissue deposits via upregula-
tion of UCP1 mRNA expression in brown adipose tis-
sue of the early period. However, we did not confirm 
the gene and protein expression changes from the early 
period to the middle or the end period of the experiment 
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in the present study. Akagiri et al. [15] reported that BTS 
did not affect UCP1 mRNA expression in brown adi-
pose tissue but increased expression in white adipose 
tissue during 4  weeks’ administration of BTS to male 
KK/Ta mice fed a high-fat diet. This suggests that these 
tissue-specific responses may depend on the experimen-
tal model (e.g., obese or diabetic model) and duration of 
BTS administration.
Hyperphagia and elevated levels of both insulin and 
leptin are common features of obesity [11–13]. Obesity is 
associated with resistance to the biological effects of both 
insulin and the satiety hormone leptin. Serum levels of 
insulin and leptin were increased in our obese mice, con-
sistent with previous studies [27]. Further, obese mice in 
this study showed elevated HOMA-IR, indicating insulin 
resistance. Leptin is a potent inhibitor of feeding and is 
expected to decrease insulin levels via inhibition of insu-
lin release [28]. In the present study, BTS improved insu-
lin resistance and reduced serum leptin (Figs.  5, 6). In 
addition, BTS increased leptin mRNA in brown adipose 
tissue but not in visceral white adipose tissue during the 
early phase of administration (Table 2). These results sug-
gest that leptin may reduce body weight through direct 
effects on both brown and white adipose tissue. In brown 
adipose tissue, increased leptin signaling may upregulate 
UCP1, leading to enhanced energy utilization and fat oxi-
dation, while increased serum leptin may reduce visceral 
white adipose tissue by enhancing triglyceride hydrolysis 
and lipid oxidation and by suppressing lipogenesis and 
adipocyte proliferation [29].
Adiponectin has been reported to be produced pre-
dominantly by normal white adipocytes but not obe-
sity-associated hypertrophic white adipocytes [30]. The 
present data showed that BTS increased adiponectin 
mRNA levels in brown adipose tissue during the early 
phase of administration (Table 2). Alternatively, BTS did 
not affect adiponectin mRNA levels in white adipose 
tissue during early administration (Table 2) and did not 
influence serum adiponectin during longer administra-
tion (Fig.  6). Adiponectin has been reported to inhibit 
UCP1 gene expression by suppressing β3-adrenergic 
receptor expression in brown adipocytes [31, 32]. It is 
therefore more likely that BTS upregulates UCP1 in 
obese mice through enhanced leptin mRNA expression 
than through enhanced adiponectin mRNA expression in 
brown adipose tissue.
The present study demonstrates that BTS has mul-
tiple anti-obesity effects in obese mice. Bofutsusho-
san reduced serum triglyceride in obese mice (Fig.  7), 
in accord with results showing that BTS also decreases 
liver triglyceride levels in obese mice (data not shown). 
However, BTS did not reduce serum or liver levels 
of HDL-cholesterol and LDL-cholesterol (Fig.  7 and 
unpublished observations). Thus, BTS may contain no 
cholesterol-lower bioactivity or else the levels of this 
bioactivity were insufficient in the sample used. Indeed, 
it is not clear which components of BTS mediate these 
specific anti-obesity action. BTS is composed with 18 
crude components (Table 1), and the BTS extract admin-
istered contained 0.80% geniposide from Gardenia, 
2.77% baicalin from Scutellaria, 0.1% sennoside A from 
Rhubarb, 0.14% total alkaloids, 0.71% glycyrrhizic acid 
from Glycyrrhiza, and 0.26% paeoniflorin from Peony. 
It has been reported that geniposide is a novel agonist 
for the glucagon-like peptide-1 (GLP-1) receptor [33]. 
Geniposide as well as GLP-1 may stimulate brown adi-
pose tissue thermogenesis through hypothalamic adeno-
sine monophosphate-activated protein kinase (AMPK) 
[34]. Thus, this geniposide component may be respon-
sible for enhanced lipolysis of serum triglycerides in 
obese mice. This notion is supported by findings that 
AMPK activation induces lipoprotein lipase (LPL) gene 
expression through PPARγ1 mRNA synthesis in skeletal 
muscle [35] and that geniposide may activate hormone-
sensitive lipase through a noradrenaline-associated 
cyclic AMP-dependent mechanism [36]. GLP-1 agonist 
such as geniposide may also release noradrenaline from 
the CNS to induce UCP1 expression in brown adipose 
tissue through noradrenaline-associated cyclic AMP-
dependent mechanisms [36]. Ephedrine, an alkaloid in 
Ephedra, acts on sympathetic nerve terminals and pro-
motes noradrenaline release. Noradrenaline induces 
thermogenesis in brown adipose tissue via β3-adrenergic 
receptor and lipolysis in white adipose tissue through 
increased cyclic AMP synthesis. Glycyrrhiza, Forsythia, 
and Schizonepeta have potent inhibitory effects on 
phosphodiesterase, resulting in increased intracellular 
cyclic AMP [14, 25], suggesting that these compound 
as well as Gardenia act synergistically to increase cyclic 
AMP signaling and downstream upregulation of UCP1 
expression in brown adipose tissue. Emodin, one of the 
active anthraquinone derivatives in Rhubarb, inhibits 
production of TNF-α and tyrosine kinase activity [37]. 
Rheinanthrone, a metabolite of Rhubarb-derived senno-
side A, activates macrophages in the colon and increases 
the secretion of prostaglandin E2 [38]. Further studies 
are warranted to assess the effects of these BTS compo-
nents on obese-related parameters in mice.
Conclusions
BTS increased mRNA expression levels of leptin, adi-
ponectin, and UCP1 in brown adipose tissue and 
improved insulin resistance in obese mice fed a high-fat 
diet. BTS subsequently reduced the serum levels of leptin 
and triglyceride with parallel decreases in the size of vis-
ceral adipocytes and visceral adipose tissue weight.
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